Free tool
Drug Trial Radar: Cardiovascular and metabolic
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
2,126
Completed, industry sponsors, Cardiovascular and metabolic, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting187
- Completed2,126
2,126 trials
Showing 1 to 25, recently updated first.
Zealand PharmaIndustry
NCT05613387 · 68 participants · Start Nov 4, 2022 · Primary completion Jun 13, 2024
Drug: ZP8396; Drug: Placebo (ZP8396) · For: Overweight; Healthy Volunteers; Obese
Sites: Neuss, Germany
- Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-339 in Healthy VolunteersCompleted
Chong Kun Dang PharmaceuticalIndustry
NCT07748702 · 77 participants · Start Sep 19, 2026 · Primary completion Oct 7, 2026
Drug: CKD-339; D311, D107 · For: Hypertension
Sites: Seoul, South Korea
BrightGene Bio-Medical Technology Co., Ltd.Industry
NCT07224399 · 60 participants · Start Oct 9, 2025 · Primary completion Jul 17, 2026
Drug: BGM1812; Placebo and 2 more · For: Healhty; Overweight or Obesity
Sites: Baltimore, Maryland
Implicit BioscienceIndustry
NCT06556810 · 10 participants · Start Oct 17, 2024 · Primary completion Aug 30, 2026
Drug: Atibuclimab (IC14) · For: Acute Decompensated Heart Failure
Sites: Charlottesville, Virginia; Richmond, Virginia
- A Study of MET233 in Individuals With Obesity or OverweightPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT07022977 · 145 participants · Start Nov 7, 2024 · Primary completion May 28, 2026
Drug: MET233; Placebo · For: Obesity and Overweight
Sites: Cypress, California
Gan & Lee Pharmaceuticals.Industry
NCT07144098 · 24 participants · Start Aug 12, 2025 · Primary completion Apr 7, 2026
Drug: GZR18 injection; GZR18 injection and 2 more · For: Obesity/Overweight
Sites: Beijing, China
- Bioequivalence Study of GZR18 Injection Before and After CMC ChangePivotal-lookingCompleted
Gan & Lee Pharmaceuticals.Industry
NCT07355738 · 266 participants · Start Jan 9, 2026 · Primary completion May 22, 2026
Drug: GZR18 injection A; GZR18 injection B · For: Obesity&T2D
Sites: Suzhou, China
Gan & Lee Pharmaceuticals.Industry
NCT07128888 · 60 participants · Start Sep 24, 2025 · Primary completion Apr 13, 2026
Drug: GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets · For: Obesity or Overweight
Sites: Beijing, China
Eilean TherapeuticsIndustry
NCT07234864 · 60 participants · Start Nov 19, 2025 · Primary completion Apr 21, 2026
Drug: ZE63-0302; Placebo · For: Type 2 Diabetes
Sites: Botany, Australia; Brisbane, Australia; Melbourne, Australia · 10 sites in all
Gan & Lee Pharmaceuticals.Industry
NCT07141030 · 32 participants · Start Apr 11, 2025 · Primary completion Oct 20, 2025
Drug: GZR18 injection · For: Obesity/Overweight
Sites: Beijing, China
- A Single Ascending Dose and Multiple Ascending Dose Trial to Assess the Dose, the Efficacy and Oro-sensitivity of Two Modified Linoleic Acids NKS-3 and NKS-5Pivotal-lookingCompleted
EktaHIndustry
NCT07924267 · 120 participants · Start Dec 10, 2025 · Primary completion Oct 10, 2026
Drug: NKS-3; NKS-5 · For: Obesity & Overweight; Overweight (BMI > 30)
Sites: Tunis, Tunisia
Hope Biosciences LLCIndustry
NCT04063215 · 24 participants · Start Jan 1, 2020 · Primary completion Oct 25, 2024
Drug: HB-adMSCs · For: Traumatic Brain Injury
Sites: Houston, Texas
- A Study of LY3549492 in Healthy Participants and Participants With Overweight or ObesityPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT07232732 · 120 participants · Start Oct 27, 2025 · Primary completion Jul 17, 2026
Drug: LY3549492 · For: Healthy; Obesity; Overweight
Sites: Daytona Beach, Florida; Dallas, Texas; Madison, Wisconsin
Chipscreen Biosciences, Ltd.Industry
NCT07511010 · 28 participants · Start Sep 10, 2026 · Primary completion Oct 22, 2026
Drug: Chiglitazar/Metformin extended-release tablets under fasting conditions; Chiglitazar/Metformin extended-release tablets after a high-fat meal and 1 more · For: T2DM (Type 2 Diabetes Mellitus)
Sites: Beijing, China
Portal Diabetes, Inc.Industry
NCT07341373 · 29 participants · Start Feb 10, 2026 · Primary completion Sep 30, 2026
Drug: Portal Insulin U-500; Portal Insulin U-500 and 3 more · For: Type 1 Diabetes
Sites: Chula Vista, California
Axxium Life, Inc.Industry
NCT05762276 · 64 participants · Start Mar 7, 2023 · Primary completion Jul 25, 2024
Drug: VXX-401; Placebo · For: Hypercholesterolemia
Sites: Brookvale, Australia; Miranda, Australia; Sydney, Australia · 5 sites in all
- A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without DiabetesPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT06924320 · 201 participants · Start Mar 6, 2025 · Primary completion Sep 29, 2026
Drug: MET233 and MET097; MET097 · For: Obesity and Obesity-related Medical Conditions
Sites: Cypress, California
AstraZenecaAstraZeneca (AZN)
NCT07216131 · 14 participants · Start Nov 10, 2025 · Primary completion Dec 30, 2025
Drug: AZD0780; Metformin · For: Healthy Participants
Sites: Brooklyn, Maryland
- JX09 SAD/MAD in Healthy ParticipantsCompleted
Ji Xing Pharmaceuticals Australia Pty LtdIndustry
NCT06183671 · 92 participants · Start Jan 18, 2024 · Primary completion Dec 31, 2024
Drug: JX09 or placebo SAD; JX09 or placebo MAD and 1 more · For: Resistant Hypertension
Sites: Melbourne, Australia
Shanghai Minwei Biotechnology Co., LtdIndustry
NCT07787728 · 40 participants · Start Jul 14, 2025 · Primary completion Dec 16, 2025
Drug: MWN109 1; MWN109 2 and 3 more · For: Overweight , Obesity
Sites: Kunming, China
Biomea Fusion Inc.Industry
NCT07223216 · 90 participants · Start Oct 23, 2025 · Primary completion Aug 12, 2026
Drug: BMF-650 · For: Obesity
Sites: Cincinnati, Ohio
- Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)Pivotal-lookingCompleted
Biomea Fusion Inc.Industry
NCT05731544 · 443 participants · Start Aug 17, 2022 · Primary completion Nov 18, 2024
Drug: BMF-219; Placebo · For: Type 2 Diabetes Mellitus
Sites: Canoga Park, California; Fountain Valley, California; La Mesa, California · 39 sites in all
NodThera Ltd. (a Rezera company)Industry
NCT06129409 · 67 participants · Start Oct 10, 2023 · Primary completion Apr 15, 2024
Drug: NT-0796 · For: Cardiovascular Diseases
Sites: Miami, Florida; Austin, Texas
Heartseed Inc.Industry
NCT04945018 · 10 participants · Start Apr 19, 2022 · Primary completion Jul 31, 2025
Drug: HS-001 CS · For: Heart Failure; Ischemic Heart Disease
Sites: Kawasaki, Japan; Saitama, Japan; Tokyo, Japan · 8 sites in all
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07884461 · 40 participants · Start Mar 29, 2025 · Primary completion Aug 24, 2026
Drug: GW906 injection; Placebo · For: Hypertension
Sites: Beijing, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.